Rohan Hockings
CEO & Executive Director
We are on time, so we will get going. Good morning, everyone. My name is Rohan Hockings. I am your host for this morning’s Second Quarter PYC Therapeutics Investor Update.
Before we begin, I’d like to make the following safe harbor statement reminding you that today’s discussion will contain forward-looking statements that involve risks and uncertainties. These risks and uncertainties are outlined in our filings with the Australian Securities Exchange. As such, actual results may differ materially from what we discuss on today’s call. The company disclaims any obligation or intention to update these statements in the future. I’d also like to notify you that the call is being recorded.
And before we start, I’d also like to say a big thank you to all of the patients and patient families who are involved in the company’s ongoing clinical trials. It’s a very bold undertaking to volunteer for a clinical trial designed to evaluate the utility of a novel therapeutic, and we are extremely grateful to those patients and their families, all of the support staff involved in the execution of those studies for joining us on that journey.
Before we begin today and get into the formal agenda, there are really only 3 points that I wanted to communicate with you. The first one, I think, has been a very good start to the year for the company. So we’re very well positioned. We’re very happy with the progress that we’ve made against the operational road map, and we’re going to go into that in quite a lot more detail. The second one is the focus of the organization now is very much on execution, and we’ll talk about why
